Ipreflavone Study - Table 1

Table 1. Osteoporosis therapies, mechanisms, benefits ad risks

Medication Primary
Benefits Risks
Conventional ERT Inhibits bone resorption Improves vasomotor symptoms of menopause Increased risk of estrogen-related cancer, venous thrombosis, hypertension, gallbladder disease.
Calcitonin Inhibits bone resorption

No estrogenic effect; analgesic effect on bone pain

Secondary hyperparathyroidism; anti-CT antibody production
Injectable: nausea, vomiting, vertigo.
Intranasal: rhinitis, nasal irritation
Bisphosphonates Inhibits bone resorption No estrogenic effect Gastric erosion, thyroid adenoma (rats); Safety of
Tx. > 4 years not known
Sodium Fluoride Stimulates osteoblasts (bone formation) Increases bone mineral density for up to 5 years Abnormal bone crystallinity; no decrease in hip fracture rate; decrease in cortical bone in favor of trabecular bone; acute GI nausea, vomiting, and hemorrhage
Selective Estrogen Receptor Modulators (Raloxifene) Inhibits bone resorption Estrogen effect on bone and lipids; not on breast or uterus Increased risk of venous thrombosis, pulmonary embolism; fatal liver toxicity; ovarian tumors and hepatic cancer (animals)
Ipriflavone Inhibits osteoclast and enhances osteoblast activity No estrogen effect; fewer side effects; analgesic effect on bone pain GI upset

Return to Ipriflavone Study

FREE Monthly Newsletters

We publish four FREE monthly email newsletters: Click Here to Subscribe to One or More Newsletters

  • Inspired Lifestyles News - Inspiring, motivating and empowering quotes, stories and articles
  • Healthy Lifestyles News - Articles, resources and products for living a healthier, more vibrant life
  • Inspired Biz News - Articles and resources for a more spiritual, whole-living work environment
  • InspiredLiving.com News & Sale Announcements - Sales events, new products and specials